Development of a porcine model of polycystic kidney disease by multiplex gene-editing.

Information

  • Research Project
  • 8834692
  • ApplicationId
    8834692
  • Core Project Number
    R43DK104500
  • Full Project Number
    1R43DK104500-01
  • Serial Number
    104500
  • FOA Number
    PA-13-092
  • Sub Project Id
  • Project Start Date
    9/10/2014 - 10 years ago
  • Project End Date
    8/31/2015 - 9 years ago
  • Program Officer Name
    MOXEY-MIMS, MARVA M.
  • Budget Start Date
    9/10/2014 - 10 years ago
  • Budget End Date
    8/31/2015 - 9 years ago
  • Fiscal Year
    2014
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/10/2014 - 10 years ago
Organizations

Development of a porcine model of polycystic kidney disease by multiplex gene-editing.

? DESCRIPTION (provided by applicant): Polycystic kidney diseases (PKD) are a group of inherited disorders characterized by progressive cyst development in the kidney resulting in bilateral renal enlargement and often end stage renal disease (ESRD). The most common form of PKD, autosomal dominant PKD occurs at a frequency of 1:400 to 1:1000. Currently, there is no treatment that can slow or reverse the growth of cysts and progression of the disease. While mouse models have been developed to characterize the pathology and progression of PKD, they tend to be poor indicators of therapeutic success in humans. We propose to develop two specific knock-in models of PKD, closely matching the genetic changes observed in human disease development. These pig models will be developed using Recombinetics exclusive license for gene-editing in livestock using TALEN technology. The resulting pigs will be evaluated for renal morphology, function, and the development of cysts, and compared to the pathology and development of PKD in patients. The development of these models is likely to revolutionize PKD research and to fast-track treatment options based on rigorous preclinical testing. Evidence of PKD development that closely resembles the human disease will justify detailed assessment in a Phase II grant and development of standard operating procedures for use of the model in preclinical testing.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    352419
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:352419\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    RECOMBINETICS, INC.
  • Organization Department
  • Organization DUNS
    829874523
  • Organization City
    SAINT PAUL
  • Organization State
    MN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    551044125
  • Organization District
    UNITED STATES